Weekly blood tests could sharpen Alzheimer's detection

NCT ID NCT06742944

Completed Knowledge-focused Sponsor: Banner Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study involved 100 adults aged 50-80 who gave blood samples weekly for 9 weeks. Researchers measured a protein called pTau-217, which is linked to Alzheimer's disease. The goal was to see how much this biomarker naturally fluctuates from week to week, which could help doctors avoid misinterpreting test results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors interpret pTau-217 blood tests more accurately, improving early detection of Alzheimer's disease.
What could go wrong: This is an observational study, not a treatment trial. It only measures biomarker variability and does not test any therapy or intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Banner Alzheimer's Institute

Phoenix, Arizona, 85006, United States
Banner Alzheimer's Institute Tucson

Tucson, Arizona, 85718, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.